An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 21 Jun 2017 Status changed from not yet recruiting to recruiting.